Something went wrong with the connection!

Manufacturing & Supply Chain

Oxford Biomedica signs new three year agreement with AstraZeneca

 Breaking News

Oxford Biomedica signs new three year agreement with AstraZeneca

Oxford Biomedica signs new three year agreement with AstraZeneca
July 05
09:48 2022
Spread the love

Oxford Biomedica, a leading gene and cell therapy group, has signed a new three year Master Services & Development Agreement with AstraZeneca UK which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine. This represents an expansion of the original Master Supply and Development Agreement announced between the two companies in September 2020.

The manufacture of COVID-19 vaccines at Oxford Biomedica’s Oxbox facility is expected to complete in the last quarter of 2022, as part of the original commitment. In accordance with the terms of the original agreement and inclusive of revenues for batches already manufactured in the first half of 2022, Oxford Biomedica expects to recognise aggregate revenues of approximately £30 million from AstraZeneca in the current financial year.

Under the new agreement, manufacturing of vaccines at Oxford Biomedica’s world class 84,000 sq ft manufacturing facility, Oxbox, will be available to AstraZeneca on an as needed basis beyond 2022.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: “I am delighted that our close partnership with AstraZeneca has been extended. I am proud of the work of all our colleagues at Oxford Biomedica that has enabled us to deliver more than 100 million doses of lifesaving COVID-19 vaccine. While contributing to the efforts to fight the pandemic, this has also demonstrated Oxford Biomedica’s ability to expand the scope of our innovative process development services and deliver high-performing manufacturing solutions beyond lentiviral vectors. We look forward to continuing to work closely with AstraZeneca and execute on our strategy to become a global leader across all viral vectors, enabling Cell and Gene Therapy companies to deliver their life-changing therapies to patients.”

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US-based subsidiary AAV manufacturing and innovation business, based near Boston. Oxford Biomedica employs more than 940 people.

About Author



Related Articles

Follow me on Twitter


New Subscriber

    Subscribe Here


    National Manufacturing Conference & Exhibition 2020

    NIBRT Springboard Success Stories